Business
Eupraxia Pharmaceuticals Doses First Patient in Phase 1b/2a Eosinophilic Esophagitis Trial
Eupraxia Pharmaceuticals Doses First Patient in Phase 1b/2a Eosinophilic Esophagitis Trial ...
About this update from Eupraxia Pharmaceuticals, Inc.
[{"type":"text","content":"\n \n \n \n Eupraxia Pharmaceuticals Doses First Patient in Phase 1b/2a Eosinophilic Esophagitis Trial\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n \n VICTORIA, BC\n \n \n ,\n \n \n June 8, 2023\n \n \n /CNW/ - Eupraxia Pharmaceuticals Inc. (\"Eupraxia\" or the \"Company\") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an innovative drug delivery technology platform, today announced that it has commenced dosing patients in its phase\n \n 1b\n \n /2a trial that is evaluating EP-104GI's safety, tolerability and efficacy as a treatment for eosinophilic esophagitis (\"EoE\").\n \n \n \"Dosing the first patient in our EoE trial is a significant achievement for the Company's clinical team and an important step towards realizing the therapeutic potential of this product candidate for a condition with significant unmet medical need,\" said Dr.\n \n James Helliwell\n \n , CEO of Eupraxia. \"We are excited to move this program forward rapidly and establish proof of concept in patients this year. Given that this is an open-label study, we expect to begin reporting results by cohort in the second half of 2023. Together with our phase 2 study of EP-104IAR in osteoarthritis of the knee, we expect to report a meaningful volume of mid-stage clinical data for our product candidate across two indications in 2023.\"\n \n \n EoE is a chronic, immune-mediated condition of the esophagus that causes inflammation, structural damage and dysfunction when left untreated. It is characterized as an \"orphan disease\" – a rare condition that affects fewer than 200,000 people in\n \n the United States\n \n , and for which exists significant unmet medical need.\n \n \n \n Current EoE Treatment Options\n \n \n \n Current EoE treatment options, which include diet changes, proton pump inhibitor therapy, slowly dissolving oral steroid tablets, monoclonal antibodies, and/or mechanical endoscopic dilation, often provide poor or temporary control over the condition.\n \n \n Oral administration of steroids, including fluticasone pro...